



Express Mail No.: EL 451598 093 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7A
n.n.
8/29/02
RECEIVED
AUG 20 2002
TECH CENTER 1600/2900

In re application of:
Lehman *et al.*

Serial No. 09/821,139

Filed: March 29, 2001

Title: NASAL ADMINISTRATION OF
AGENTS FOR THE TREATMENT OF
GASTROPARESIS

Group Art Unit: 1616

Examiner: Haghighatian, M.

Attorney Docket No. 7960-131

Confirmation No.: 5628

Date: August 14, 2002

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 14, 2002, and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit herewith: (a) an Amendment Fee Transmittal Sheet (in duplicate) accompanied by the appropriate fee; (b) a petition for extension of time for three (3) months from May 14, 2002 to and including August 14, 2002; (c) Appendix A showing marked up amendments to the specification; (d) Appendix B showing all pending claims; and (e) Information disclosure statement with List of References Cited and a copy of cited reference.

08/19/2002 MGE BREM1 00000105 161150 09821139

01 FC:103 576.00 CH

AMENDMENT

In the Specification:

Please replace the paragraph beginning at page 9, line 28, and ending at page 10, line 2, with the following:

A' A typical MCP nasal formulation is in solution form having a light amber color and being non-cloudy to the naked eye with an pH of between about 3.0-5.0. The typical formulation may contain benzyl alcohol of at least about 13.5 mg/ml containing practically no